These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35093266)

  • 21. A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.
    Gregg A; Getz N; Benger J; Anderson A
    Ther Innov Regul Sci; 2020 May; 54(3):485-491. PubMed ID: 33301131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supplemental oxygen therapy recommendations in patients with sickle cell disease during air travel: A cross-sectional survey of North American health care providers.
    Padda A; Corriveau-Bourque C; Belletrutti M; Bruce AAK
    Paediatr Child Health; 2020 Mar; 25(2):107-112. PubMed ID: 33390748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic counseling in sickle cell disease: Insights from the Indian tribal population.
    Aggarwal P; Bhat D
    J Community Genet; 2023 Aug; 14(4):345-353. PubMed ID: 37540483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America.
    Winn A; Basu A; Ramsey SD
    Pharmacoecon Open; 2023 Mar; 7(2):313-320. PubMed ID: 36773220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report.
    Yates AM; Aygun B; Nuss R; Rogers ZR; ;
    Pediatrics; 2024 Jul; ():. PubMed ID: 39034826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of community outreach and engagement in recruitment success for a prebirth cohort.
    Tigges BB; Kaar JL; Erbstein N; Silberman P; Winseck K; Lopez-Class M; Burbacher TM
    J Clin Transl Sci; 2017 Jun; 1(3):184-191. PubMed ID: 29082032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in pharmacotherapy for sickle cell disease: what is the current state of play?
    Alan S; Kanter J
    Expert Opin Pharmacother; 2024 Jul; ():1-10. PubMed ID: 38973339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The challenge of eliciting opinions of gene therapy for SCD.
    Limerick EM; Fitzhugh CD
    Blood Adv; 2023 Dec; 7(23):7369-7370. PubMed ID: 38085553
    [No Abstract]   [Full Text] [Related]  

  • 29. Nothing about us without us: Advocacy and engagement in genetic medicine.
    Olayiwola O; Castillejo A; Louella M; Supercharger M; Harlow E; Dee L; Abdallah K; Kityo-Mutuluuza C; Adair JE; Orentas R; Dubé K
    Sci Transl Med; 2024 May; 16(746):eadn2401. PubMed ID: 38718133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engaging Our Communities in Active Participation in Clinical Trials: It's a Matter of Trust.
    Maron JL
    Clin Ther; 2024 May; 46(5):381. PubMed ID: 38796337
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial: Building capacity for sickle cell disease research and healthcare.
    Nembaware V; Nnodu OE; Sangeda RZ; Paintsil V; Mazandu GK; Munung NS; Wonkam A; Martí-Carvajal AJ
    Front Genet; 2023; 14():1226589. PubMed ID: 37501718
    [No Abstract]   [Full Text] [Related]  

  • 32. The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease.
    Desine S; Hollister BM; Abdallah KE; Persaud A; Hull SC; Bonham VL
    AJOB Empir Bioeth; 2020; 11(4):195-207. PubMed ID: 33044907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers.
    Lee LH; Whisenton LH; Benger J; Lanzkron S
    Blood Adv; 2021 Dec; 5(23):5323-5331. PubMed ID: 34543385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Integrative Review: The Evolution of Provider Knowledge, Attitudes, Perceptions and Perceived Barriers to Caring for Patients with Sickle Cell Disease 1970-Now.
    Reich J; Cantrell MA; Smeltzer SC
    J Pediatr Hematol Oncol Nurs; 2023; 40(1):43-64. PubMed ID: 35854420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation.
    Byrnes C; Botello-Harbaum M; Clemons T; Bailey L; Valdes KM; Coleman-Cowger VH
    J Natl Med Assoc; 2022 Apr; 114(2):211-217. PubMed ID: 35093266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework.
    Badawy SM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):196-205. PubMed ID: 34889394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective.
    Masese RV; Bulgin D; Douglas C; Shah N; Tanabe P
    PLoS One; 2019; 14(5):e0216414. PubMed ID: 31063506
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.